Short- And long-term changes of quality of life in patients with acromegaly: Results from a prospective study

Journal of Endocrinological Investigation

Volumn 33, Issue 1, 2010, Pages 20-25

  Sardella, C ^a   Lombardi, M ^a   Rossi, G ^b   Cosci, C ^a   Brogioni, S ^a   Scattina, I ^a   Webb, S M ^c   Gasperi, M ^d   Martino, E ^a   Bogazzi, F ^a  

^a UNIVERSITY OF PISA   (Italy)

^b INSTITUTE OF CLINICAL PHYSIOLOGY   (Italy)

^c UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^d UNIVERSITY OF MOLISE   (Italy)

Author keywords

Acromegaly; ACROQOL; GH; IGF I; Quality of life

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1; SOMATOSTATIN;

ACROMEGALY; ADULT; ARTICLE; CONTROLLED STUDY; DISEASE CONTROL; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; PATIENT ASSESSMENT; QUALITY OF LIFE; STRUCTURED QUESTIONNAIRE;

EID: 77950543666     PISSN: 03914097     EISSN: 17208386     Source Type: Journal    
DOI: 10.1007/BF03346555     Document Type: Article

References (24)

1. Melmed S. Medical progress: Acromegaly. N Engl J Med 2006, 355: 2558-2573
2. Dekkers OM, Biermasz NR, Pereira AM, Romijn JA Vandenbroucke JP. Mortality in acromegaly: a metaanalysis. J Clin Endocrinol Metab 2008, 93: 61-67
3. Colao A, Ferone D, Marzullo P, Lombardi G. Systemic complications of acromegaly: epidemiology, pathogenesis, and management. Endocr Rev 2004, 25:102-52.
4. Orme SM, McNally RJ, Cartwright RA, Belchetz PE. Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. J Clin Endocrinol Metab 1998, 83: 2730-2734
5. Webb SM, Prieto L, Badia X, et al. Acromegaly Quality of Life Questionnaire (ACROQOL) a new health-related quality of life questionnaire for patients with acromegaly: development and psychometric properties. Clin Endocrinol (Oxf) 2002, 57: 251-258
6. Bates AS, Van't Hoff W, Jones JM, Clayton RN. An audit of outcome of treatment in acromegaly. Q J Med 1993, 86: 293-299
7. Biermasz NR, van Thiel SW, Pereira AM, et al. Decreased quality of life in patients with acromegaly despite long-term cure of growth hormone excess. J Clin Endocrinol and Metab 2004, 89: 5369-5376
8. Biermasz NR, Pereira AM, Smit JW, Romijn JA, Roelfsema F. Morbidity after long-term remission for acromegaly: persisting joint-related complaints cause reduced quality of life. J Clin Endocrinol Metab 2005, 90: 2731-2739
9. Kauppinen-Makelin R, Sane T, Sintonen H et al. Finnish Acromegaly Study Group. Quality of life in treated patients with acromegaly. J Clin Endocrinol Metab 2006, 91: 3891-3896
10. Rowles S, Prieto L, Badia X, Shalet SM, Webb SM, Trainer PJ. Quality of life (QOL) in patients with acromegaly is severly impaired: use of a novel measure of QOL: acromegaly quality of life questionnaire. J Clin Endocrinol Metab 2005, 90: 3337-3341
11. Paisley AN, Rowles SV, Roberts ME, et al. Treatment of acromegaly improves quality of life, measured by AcroQol. Clin Endocrinol (Oxf) 2007, 67: 358-362
12. Colao A, Martino E, Cappabianca P et al. First-line therapy of acromegaly: a statement of the A.L.I.C.E. (Acromegaly primary medical treatment Learning and Improvement with Continuous Medical Education) Study Group. J Endocrinol Invest 2006, 29: 1017-1020
13. Gola M, Bonadonna S, Mazziotti G, Amato G, Giustina A. Resistance to somatostatin analogs in acromegaly: An evolving concept? J Endocrinol Invest 2006, 29: 86-93.
14. Colao A, Amaldi G, Beck-Peccoz P, et al. Pegvisomant in acromegaly: why, when, how. J Endocrinol Invest 2007, 30: 693-699
15. Giustina A, Mancini T, Boscani PF, et al. Assessment of the awareness and management of cardiovascular complications of acromegaly in Italy. The COM.E.T.A. (COMorbidities Evaluation and Treatment in Acromegaly) Study. J Endocrinol Invest 2008, 31 : 731-738
16. Glantz SA. Primer of Biostatistics. New York: McGraw-Hill, 2002.
17. StatXact 4, version 4.0.1. Cytel Software Corporation, Cambridge, MA, USA.
18. Sonino N, Scarpa E, Paoletta A, Fallo F, Boscaro M. Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychother Psychosom 1999, 68: 165-167
19. Gilbert J, Ketchen M, Kane P et al. The treatment of de novo acromegalic patients with octreotide-LAR: efficacy, tolerability and cardiovascular effects. Pituitary 2003, 6: 11-18
20. Webb SM, Badia X, Surinach N; Spanish AcroQol Study Group. Validity and clinical applicability of the acromegaly quality of life questionnaire, AcroQol: a 6-month prospective study. Eur J Endocrinol 2006, 155: 269-277
21. Hua SC, Yan YH, Chang TC. Associations of remission status and lanreotide treatment with quality of life in patients with treated acromegaly. Eur J Endocrinol 2006, 155: 831-837
22. Woodhouse U, Mukherjee A, Shalet SM, Ezzat S. The influence of growth hormone status on physical impairments, functional limitations, and health-related quality of life in adults. Endocr Rev 2006, 27: 287-317.
23. Aberg ND, Brywe KG, Isgaard J. Aspects of growth hormone and insulin-like growth factor-I related to neuroprotection, regeneration and functional plasticity in the adult brain. ScientificWorld-Joumal 2006, 6: 53-80.
24. Matta M, Couture E, Cazals L, Vezzosi D, Bennet A, Caron P. Impaired quality of life of ppatients with acromegaly: control of GH/IGF-I excess improves psychological subscale appearance. Eur J Endocrinol 2008, 158: 305-310